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Abstract: Diabetic kidney disease affects up to forty percent of patients with diabetes during their 
lifespan. Prevention and treatment of diabetic kidney disease is currently based on optimal 
glucose and blood pressure control. Renin–angiotensin aldosterone inhibitors are considered the 
mainstay treatment for hypertension in diabetic patients, especially in the presence of 
albuminuria. Whether strict blood pressure reduction entails a favorable renal outcome also in 
non-albuminuric patients is at present unclear. Results of several clinical trials suggest that an 
overly aggressive blood pressure reduction, especially in the context of profound pharmacologic 
inhibition of the renin–angiotensin–aldosterone system may result in a paradoxical worsening of 
renal function. On the basis of this evidence, it is proposed that blood pressure reduction should 
be tailored in each individual patient according to renal phenotype. 
Keywords: diabetes; blood pressure target; RAAS inhibitors; SGLT-2 inhibitors; renal outcome; 
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1. Introduction 
Diabetic kidney disease (DKD) is a relatively common and feared complication of both type 1 
and 2 diabetes. It affects 30% to 40% of diabetic patients over their lifespan and negatively impacts 
their cardiovascular risk burden and overall survival [1]. Retarding the progression of overt DKD to 
end-stage renal disease (ESRD) has proved a challenging task and prevention of its onset may well 
be a more cost-effective strategy to reduce the burden of risk for these patients. Among established 
therapeutic interventions, beside optimal glucose control [2,3], antihypertensive treatment by 
means of renin–angiotensin–aldosterone system inhibitors (RAAS-is) has traditionally been 
considered the treatment of choice [4]. However, the effectiveness of this intervention in real-life 
clinical conditions has probably been overemphasized, and optimal blood pressure (BP) values in 
order to maximize the treatment benefit are still a matter of debate [5]. 
A recently published retrospective study while confirming that long-term, strict control of BP 
is associated to a reduction of albuminuria suggested that the related benefit in terms of glomerular 
filtration rate (GFR) preservation may be smaller than anticipated because of a paradoxical 
worsening in renal function at very low BP levels [6]. As a matter of fact, several other studies seem 
to confirm these data, indicating a lack of renal benefit when very low BP values are achieved [7,8]. 
This could probably be related to an impaired adaptation of intra-renal hemodynamics to BP 
variations because of vascular stiffening and atherosclerosis. 
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Experimental and clinical studies have convincingly demonstrated the involvement of 
increased activity of the RAAS both at the systemic and tissue level in the development and 
progression of diabetic renal damage [9]. Thus, RAAS-is are considered the mainstay treatment of 
hypertension in diabetic patients, particularly in those patients with overt proteinuria [4]. 
angiotensin-converting-enzyme inhibitor (ACE-is) and angiotensin II receptor blockers (ARBs) have 
been shown to effectively improve intra-renal hemodynamics, thereby conveying long-term renal 
protection. Moreover, RAAS-is are known to attenuate interstitial fibrosis and glomerular sclerosis 
at the renal tissue level via multiple mechanisms, including a reduction of angiotensin II action as 
well as a reduction in the production of platelet-derived growth factor and connective tissue 
growth factors [10]. 
Albuminuria is a known marker of kidney damage with an established prognostic role both in 
cardiovascular and in renal risk. Recent, long-term studies confirm that a decrease in albuminuria 
obtained with optimal BP control is associated with better cardiovascular and renal outcome, while 
an increase in urine albumin excretion over time entails worse prognosis [11,12]. Thus, one might 
state that changes in albuminuria translate in parallel changes of risk and albuminuria reduction 
could be taken as a treatment target in itself [13]. However, recent studies have shown that both in 
Type 2 and Type 1 diabetes, CKD is a rather heterogeneous phenotype, with different underlying 
histologic patterns, with fibrosis and ischemia variably involving glomeruli and the interstitium 
[14]. Indeed, recent surveys seem to indicate that albuminuria is absent or minimal in a 
considerable proportion of diabetic patients presenting with declining renal function [15]. 
While lower BP values and maximal pharmacologic inhibition of the RAAS have consistently 
been shown to improve renal outcome in diabetic patients presenting with the traditional 
“albuminuric” renal phenotype, it is uncertain whether a similar therapeutic strategy should be 
applied in the absence of albuminuria. Thus, on the basis of more recent epidemiological data, it has 
been proposed that antihypertensive treatment should be individualized both in terms of target BP 
values and possibly, in terms of antihypertensive drugs combination according to different 
presenting renal phenotypes [5]. 
2. Blood Pressure Reduction and Renal Protection: Which is the Target Value? 
GFR and albuminuria are usually considered to be valid biomarkers that can be used to 
monitor renal function and to assess the effectiveness of therapeutic strategies for renal protection 
[16]. The results of many clinical trials have shown that changes in albuminuria over time are 
related to cardiovascular and renal protection, emphasizing the usefulness of achieving optimal BP 
targets in clinical practice [12]. Two recent meta-analyses [11,17] seem to confirm a benefit in terms 
of cardiovascular and renal risk when a reduction of albuminuria is obtained, independent of BP 
reduction and the type of antihypertensive treatment. On the basis of these results, reduction in 
albuminuria has been proposed as an independent target of treatment [18]. However, there have 
also been conflicting views about the significance of albuminuria changes in relation to renal 
outcome. In fact, albuminuria and GFR modifications may follow different paths in time under the 
effect of antihypertensive treatment. Some studies suggest that reduction of albuminuria may in 
part be the result of GFR reduction itself and caution should be taken when interpreting data, 
especially in the short-term [6]. Recently, a large trial has compared two different therapeutic 
regimens aimed at lowering BP either to below 140 or below 120 mmHg in a large group of patients 
with high cardiovascular risk [19]. More intensive BP reduction was generally associated to better 
cardiovascular outcome and lower mortality, although no benefit on renal endpoints was evident, 
and some renal function worsening was even present in specific subgroups. These results, however, 
seem to be difficult to translate into clinical practice due to severe methodological limitations in the 
study, especially regarding the technique of BP recording [20]. Nonetheless, results of the SPRINT 
study conducted in a non-diabetic cohort seem to be in line with those from the ACCORD study, 
carried out in patients with Type 2 diabetes. In fact, the latter showed that intensive BP control is 
not associated to cardiovascular and renal protection, with the only exception being the risk of 
stroke, which keeps decreasing at very low BP levels. Furthermore, two meta-analyses have shown 
Medicina 2019, 55, 382 3 of 6 
that low BP is associated with better cardiovascular protection in patients at high risk, including 
those with diabetes [7,8]. However, cardiovascular benefits seem to fade at BP values below 130 
mmHg and lower values (i.e., below 120 mmHg) may even entail more risk than benefit, with the 
only exception of further reduction in cerebrovascular events. Based on this evidence, International 
Guidelines have recently revised recommendations on optimal BP values indicating that high-risk 
patients, such as those with CKD and/or diabetes, should be treated to achieve systolic BP values 
<130 mmHg. Interestingly though, current European Guidelines [4] also recommend, for the first 
time, a threshold below which BP should not be lowered further in these patients to prevent a 
paradoxical increase in morbidity and mortality. Considering the positive correlation between the 
degree of albuminuria and risk of renal progression, patients with proteinuria should be 
maintained at a BP value below 130 mmHg and possibly even lower [21]. In the absence of 
albuminuria, a BP target below 130 mmHg but above 120 mmHg appears to be wise [22]. Real-life 
data seem to confirm that a J-curve describes the relationship between BP reduction and renal 
morbidity. In the Italian Associazione Medici Diabetologi (AMD) database, GFR was worse in the 
subgroup of patients with a systolic BP under 130 mmHg [23]. 
Many diabetic hypertensive patients may suffer from autonomic neuropathy, and therefore, 
from orthostatic hypotension and other features of impaired systemic hemodynamics. Thus, in 
clinical practice, seated or standing BP should be used as a target for treatment and great care 
should be paid when titrating antihypertensive drugs, especially peripheral alfa-blocking drugs. In 
addition, the timing of drug administration should be tailored in each individual patient and 
attention should be paid to avoid the risk of haemodynamic changes in patients in the presence of 
diarrhea or hypovolemia. 
3. Glomerular Haemodynamics as a Target for Treatment: Have We Reached the Limit? 
RAAS inhibitors are considered the mainstay treatment for a variety of cardiovascular 
conditions such as of hypertension, diabetes, proteinuria, and heart failure and myocardial 
infarction because of their beneficial effects on cardiovascular protection [4]. In particular, the effect 
on renal protection is related to anti-fibrotic properties and the reduction of proteinuria. Start and 
up-titration of RAAS-is are often the causes of acute worsening in renal function which could have 
been monitored [24]. A real-life study, conducted in 2017 on more than 100,000 patients with 
different comorbidities in the UK, investigated the relationship between worsening renal function 
and cardiovascular and renal outcome after initiation of RAAS-is. This study showed that the 
decline of GFR was related to adverse cardio renal outcomes [25]. Additional doubts on the renal 
safety of multiple pharmacological interventions have been raised in recent years. Different trials 
such as ONTARGET, ALTITUDE and NEPHRON D showed in a variety of high-risk patients that 
profound blockade of RAAS results in greater loss of renal function and higher risk of hyper-
kalemia with no advantages in short- or long-term renal outcomes [26–28]. 
Recently, sodium/glucose cotransporter 2 inhibitors (SGLT2-is) have received attention as a 
class of promising hypoglycemic agents with additional ability to slow down the progression of 
diabetic kidney disease. They improve glucose metabolism by inhibiting glucose reabsorption at the 
proximal part of the renal tubule, thereby increasing glycosuria. Moreover, SGLT2-is have been 
shown to improve the systemic hemodynamic profile by reducing BP and promoting weight loss. 
While renal changes observed with the use of these agents may be due to multiple pathogenic 
mechanisms, a large part of their renal protective effect seems to be mediated by their ability to 
favorably interfere with renal hemodynamics. In fact, SGLT2-is attenuate hyperfiltration and lower 
intra-glomerular pressure by increasing afferent arteriolar vaso-constriction, as a consequence of 
tubular glomerular feed-back activation at the macula densa [29]. Besides these hemodynamic 
effects, renal protection is increased by a number of favorable metabolic effects. In fact, weight loss 
and a negative caloric balance are fostered by urinary loss of glucose. Increased glucagone 
production and reduced insulin release may promote gluconeogenesis and lipolysis and translate 
into a reduction of fat tissue. In addition, the observed uricosuric effect due to decreased GLUT-9-
mediated urate reabsorption at the tubular level may contribute to an improvement in the 
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cardiorenal metabolic profile. Ischemic renal damage may further be prevented through other still 
uncertain mechanisms such as the increase of hypoxia-inducible factor production and reduction in 
vascular stiffness [30]. The reno-protective properties of glycosuric agents is additional to that of 
traditional RAAS-is and appears to complement it. 
It has been estimated that by using SGLT2-is in addition to RAAS-is, an additional 30%–40% 
renal protection benefit could be obtained in clinical practice. While this approach looks very 
promising and deserves to be implemented in a general systematic way in diabetic patients at renal 
risk, it may hardly represent the ultimate strategy to effectively prevent this devastating micro-
vascular complication. From what we know of the complex, multifactorial mechanisms underlying 
the pathogenesis of diabetic renal disease, it is conceivable that, in order to obtain additional reno-
protection, mechanisms that differ from glomerular hemodynamics should also be targeted. In fact, 
it is feasible that by combining SGLT2-is and RAAS-is, intra-glomerular pressure (and therefore, 
filtration fraction) may be reduced to a point beyond which further reduction may entail harm (i.e., 
GFR reduction) rather than a long-term benefit. In this perspective, other attractive agents such as 
neprilysin-inhibitors or GLP1R-A, which exert their renal protective action by means of different 
mechanisms, may soon prove their incremental value in providing kidney protection. Neprilysin 
inhibitors have potential in improving glucose homeostasis in patients with diabetes through 
increasing muscle sensitivity to glucose uptake and hepatic sensitivity to insulin. The simultaneous 
use of RAAS-is can make-up for the negative effects of increasing angiotensin II levels through 
neprilysin inhibition. The association of these two drugs could provide an efficacious 
cardiovascular and renal protection in combination with positive effects on glucose homeostasis 
[31]. 
4. Conclusions 
In conclusion, optimal BP reduction by antihypertensive treatment currently remains the most 
effective and safe intervention to convey renal and cardiovascular protection in patients with 
diabetic kidney disease. RAAS-I should be considered the treatment of choice, although ideal BP 
values remain a matter of debate. Lower targets are recommended in the presence of overt 
albuminuria, a condition that entails greater risk of renal progression. A paradoxical J-curve 
relationship between BP reduction and renal morbidity may limit the benefit of aggressive 
treatment strategies, especially in the frail, elderly patients with non-albuminuric renal impairment. 
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